Detalhe da pesquisa
1.
Effective drug combinations in breast, colon and pancreatic cancer cells.
Nature
; 603(7899): 166-173, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197630
2.
canSAR: update to the cancer translational research and drug discovery knowledgebase.
Nucleic Acids Res
; 49(D1): D1074-D1082, 2021 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33219674
3.
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Br J Cancer
; 124(5): 951-962, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33339894
4.
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Mol Syst Biol
; 16(7): e9405, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32627965
5.
canSAR: update to the cancer translational research and drug discovery knowledgebase.
Nucleic Acids Res
; 47(D1): D917-D922, 2019 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30496479
6.
canSAR: an updated cancer research and drug discovery knowledgebase.
Nucleic Acids Res
; 44(D1): D938-43, 2016 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26673713
7.
canSAR: updated cancer research and drug discovery knowledgebase.
Nucleic Acids Res
; 42(Database issue): D1040-7, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24304894
8.
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Cancer Discov
; 14(5): 846-865, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456804
9.
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
Mol Cancer Ther
; 21(6): 1020-1029, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368084
10.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kß/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Oncogene
; 41(46): 5046-5060, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36241868
11.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273059
12.
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Clin Cancer Res
; 26(24): 6535-6549, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988967
13.
Simulated ablation for detection of cells impacting paracrine signalling in histology analysis.
Math Med Biol
; 36(1): 93-112, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29452382
14.
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Mol Cancer Ther
; 18(8): 1396-1404, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262731
15.
Leveraging Human Genetics to Guide Cancer Drug Development.
JCO Clin Cancer Inform
; 2: 1-11, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30652614
16.
SiGNet: A signaling network data simulator to enable signaling network inference.
PLoS One
; 12(5): e0177701, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28545060